P/F Program The objectives of Pilot and Feasibility (P/F) Program are to provide a mechanism for enhancing interdisciplinary research projects for junior faculty and to promote career development in digestive diseases. Since 1999, 56/58 awards have been to investigators at the Assistant Professor level or more junior (Track 1), and 14/15 since 2013. Since 1999, the P/F Program has an overall Return on Investment (ROI) of 58:1. We have established a detailed and rigorous peer-review process to select the most meritorious proposals from applicants with the greatest potential. We assure constructive and interactive feedback through email, phone and face-to-face discussions and meetings with all the applicants prior to application and written critiques following review. We receive 9-15 applications each year, with 4-5 funded following internal and external review with final priority assigned by our External Advisory Board.
SPECIFIC AIMS The Program is advertised and promoted within the Washington University community with two key objectives:
Aim 1 : To provide funds that spur creative proposals that help faculty establish independent, extramurally funded programs in digestive disease research, facilitate expansion of the Research Base, and attract new ideas to the field of digestive disease as a whole.
Aim 2 : To provide a crucial mechanism to promote career development of new investigators, particularly emerging junior faculty (Track 1). The WU-DDRCC P/F Program funds junior investigators at a critical juncture in their career when preliminary data could mean the difference between successful extramural funding and building a career in GI research vs. pursuing either non-GI research or other career goals entirely. ACCOMPLISHMENTS AND HIGHLIGHTS. Between 2003-18 (15 P/F cycles), we funded 43 investigators with total investment of $1,551,372 (average: $36,078/award). Those P/F Awardees in turn have received $59.8M in total direct costs for an ROI of 39:1. Our ROI for the last cycle (2013-18) is 26:1. 95% of our P/F Awardees are still engaged in full-time academic research, with 72% (31/43) obtaining subsequent independent funding (33 R01, 6 R21, 4 R03, 6 K awards (1 K01, 2 K23, 4 K08), 3 ACS). P/F funding has led to our P/F Awardees publishing numerous high impact publications in Science (Lora Hooper), Nature (Newberry), and Cell (Stappenbeck, Ting Wang). In the last four years alone, our Awardees have published their P/F work in Nature Commun (DeBosch), Hepatology (Rudnick), Cell Host Microbe (Mysorekar, Xiaochao Wei), and Nat Methods (Ting Wang). The P/F Program is run by Dr. Jason Mills, closely coordinated with Drs. Davidson and Tarr. Together, they recruit new junior candidates across basic and clinical Departments at Washington University, bringing a considerable breadth of new, junior investigators into GI research. Since the last renewal, P/F Awardees have come from a diverse set of departmental backgrounds: Medicine (GI, Oncology, Hematology, Infectious Disease, Nutrition, Cardiology, Endocrinology Divisions), Pediatrics (GI, Rheumatology), Pathology & Immunology, Developmental Biology, Genetics, Obstetrics & Gynecology.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Center Core Grants (P30)
Project #
2P30DK052574-21
Application #
9888923
Study Section
Special Emphasis Panel (ZDK1)
Project Start
Project End
Budget Start
2019-12-01
Budget End
2020-11-30
Support Year
21
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Funk, Steven D; Bayer, Raymond H; Malone, Andrew F et al. (2018) Pathogenicity of a Human Laminin ?2 Mutation Revealed in Models of Alport Syndrome. J Am Soc Nephrol 29:949-960
Schnadower, David; Tarr, Phillip I; Casper, T Charles et al. (2018) Lactobacillus rhamnosus GG versus Placebo for Acute Gastroenteritis in Children. N Engl J Med 379:2002-2014
VanDussen, Kelli L; Stojmirovi?, Aleksandar; Li, Katherine et al. (2018) Abnormal Small Intestinal Epithelial Microvilli in Patients With Crohn's Disease. Gastroenterology 155:815-828
Davidson, Nicholas O (2018) Tie-ing up angiogenesis to treat NASH. Hepatology :
Engelstad, Holly J; Barron, Lauren; Moen, Joseph et al. (2018) Remnant Small Bowel Length in Pediatric Short Bowel Syndrome and the Correlation with Intestinal Dysbiosis and Linear Growth. J Am Coll Surg 227:439-449
Rusconi, B; Jiang, X; Sidhu, R et al. (2018) Gut Sphingolipid Composition as a Prelude to Necrotizing Enterocolitis. Sci Rep 8:10984
Knoop, Kathryn A; Newberry, Rodney D (2018) Goblet cells: multifaceted players in immunity at mucosal surfaces. Mucosal Immunol 11:1551-1557
Choi, Jaebok; Cooper, Matthew L; Staser, Karl et al. (2018) Baricitinib-induced blockade of interferon gamma receptor and interleukin-6 receptor for the prevention and treatment of graft-versus-host disease. Leukemia 32:2483-2494
Mills, Jason C; Samuelson, Linda C (2018) Past Questions and Current Understanding About Gastric Cancer. Gastroenterology 155:939-944
Vishy, Courtney E; Swietlicki, Elzbieta A; Gazit, Vered et al. (2018) Epimorphin regulates the intestinal stem cell niche via effects on the stromal microenvironment. Am J Physiol Gastrointest Liver Physiol 315:G185-G194

Showing the most recent 10 out of 899 publications